glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Glucagon-like peptide 1 receptor agonists:
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Glucagon-like peptide 1 receptor agonists:](https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41569-023-00849-3/MediaObjects/41569_2023_849_Fig1_HTML.png)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Glucagon-like peptide 1 receptor agonists:](https://www.frontiersin.org/files/Articles/1431292/xml-images/fendo-15-1431292-g001.webp)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Glucagon-like peptide 1 receptor agonists:](https://www.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/721135/fendo-12-721135-HTML/image_m/fendo-12-721135-g001.jpg)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Glucagon-like peptide 1 receptor agonists:](https://static.wixstatic.com/media/966baf_6c1aec6e92ad4edc9475497a98bba2d1~mv2.jpg/v1/fill/w_960,h_540,al_c,q_85,enc_avif,quality_auto/966baf_6c1aec6e92ad4edc9475497a98bba2d1~mv2.jpg)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Glucagon-like peptide 1 receptor agonists:](https://www.mdpi.com/jcm/jcm-12-00145/article_deploy/html/images/jcm-12-00145-g001.png)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Glucagon-like peptide 1 receptor agonists:](https://www.mdpi.com/jcm/jcm-15-03330/article_deploy/html/images/jcm-15-03330-g002-550.jpg)






















